Pharvaris NV reports results for the quarter ended in June - Earnings Summary

Pharvaris NV

14/08/2024 13:38

* Pharvaris NV  PHVS.OQ  reported a quarterly adjusted loss
of 55
cents​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -63
cents.  The mean expectation of six analysts for the quarter was
for a loss of 55 cents per share. Wall Street expected
results to range from -61 cents to -47 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Pharvaris NV's reported EPS for the quarter was a loss
of 55
cents​.
    * The company reported a quarterly loss of €29.73 million.
    * Pharvaris NV shares had fallen by 2.8% this quarter and
lost 34.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Pharvaris NV is
$32.00 
This summary was machine generated from LSEG data August 14 at
12:37 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.55          -0.55          Met
 Mar. 31 2024      -0.56          -0.52          Beat
 Dec. 31 2023      -0.53          -0.76          Missed
 Sep. 30 2023      -0.60          -0.58          Beat